帕拉曼奈尔对儿科患者的有效性和安全性:来自中国的现实研究
Xiaohui Wang1, Taoyun Ji2, Maomao Liu3
1Department of Neurology Beijing Children's Hospital Capital Medical University, National Center for Children's Health Beijing China.
Pediatric investigation
|June 20, 2025
概括
珀兰 (PER) 有效地降低了中国儿科患者的发作频率,显示出良好的保留率. 该研究发现,在耐火性的儿童中,PER安全用于辅助治疗.
科学领域:
- 儿科神经学 儿科神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 临床药理学 临床药理学
背景情况:
- 有限的数据存在于perampanel (PER) 在中国儿童的使用,特别是那些耐火性.
- 佩拉曼奈尔是治疗的辅助疗法,但其在儿童群体中的使用程度不如成年人那么稳定.
研究的目的:
- 评估中国儿童和青少年患的帕拉曼内尔 (PER) 的有效性,保留和安全性.
- 解决这个人口群体中缺乏PER的大规模临床数据的问题,特别是对于耐火病例.
主要方法:
- 一个多中心,前性,观察性研究.
- 招募了240名接受PER作为辅助治疗的儿童和青少年.
- 在6个月内评估了发作频率减少 (主要终点),留率,发作自由度和治疗出现的不良事件 (TEAE).
主要成果:
- 70.4%的患者在6个月后实现了≥50%的发作频率降低.
- 22.1%的患者没有发作,其保留率为90.2%.
- 89名患者 (37.1%) 经历了TEAE,导致7例患者停止治疗;没有报告严重的TEAE.
结论:
- 在常规的临床环境下,Perampanel (PER) 在中国儿科患者中表现出良好的有效性和保留时间.
- 是一种可行的,安全的辅助治疗选择,适用于患有的儿童和青少年,包括那些患有难治性的人.
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...